References
- Alblas J, Slager-Davidov R, Steenbergh PH, Sussenbach JS, van der Burg B. 1998. The role of MAP kinase in TPA-mediated cell cycle arrest of human breast cancer cells. Oncogene. 16:131–139.10.1038/sj.onc.1201485
- Anand P, Thomas SG, Kunnumakkara AB, Sundaram C, Harikumar KB, Sung B. 2008. Biological activities of curcumin and its analogues (Congeners) made by man and Mother Nature. Biochem Pharmacol. 76:1590–1611.10.1016/j.bcp.2008.08.008
- Blechacz BR, Smoot RL, Bronk SF, Werneburg NW, Sirica AE, Gores GJ. 2009. Sorafenib inhibits signal transducer and activator of transcription-3 signaling in cholangiocarcinoma cells by activating the phosphatase shatterproof 2. Hepatology. 50:1861–1870.10.1002/hep.23214
- Brognard J, Clark AS, Ni Y, Dennis PA. 2001. Akt/protein kinase B is constitutively active in non-small cell lung cancer cells and promotes cellular survival and resistance to chemotherapy and radiation. Cancer Res. 61:3986–3997.
- Chang F, Lee JT, Navolanic PM, Steelman LS, Shelton JG, Blalock WL, Franklin RA, McCubrey JA. 2003. Involvement of PI3K/Akt pathway in cell cycle progression, apoptosis, and neoplastic transformation: a target for cancer chemotherapy. Leukemia. 17:590–603.10.1038/sj.leu.2402824
- Courtney KD, Corcoran RB, Engelman JA. 2010. The PI3K pathway as drug target in human cancer. J Clin Oncol. 28:1075–1083.10.1200/JCO.2009.25.3641
- Eshghi N, Asnaashari M, Khodaparast MH, Hosseini F. 2014. Evaluating the potential of natural curcumin for oxidative stability of soybean oil. Nat Prod Res. 28:1375–1378.10.1080/14786419.2014.901319
- Huether A, Höpfner M, Baradari V, Schuppan D, Scherübl H. 2007. Sorafenib alone or as combination therapy for growth control of cholangiocarcinoma. Biochem Pharmacol. 73:1308–1317.10.1016/j.bcp.2006.12.031
- Kanitkar M, Gokhale K, Galande S, Bhonde RR. 2008. Novel role of curcumin in the prevention of cytokine-induced islet death in vitro and diabetogenesis in vivo. Br J Pharmacol. 155:702–713.
- Kolch W. 2000. Meaningful relationships: the regulation of the Ras/Raf/MEK/ERK pathway by protein interactions. Biochem J. 351:289–305.10.1042/0264-6021:3510289
- Liu JF, Liu JJ, Xu HY, Zhang YM, Chu LP, Liu QF, Song NL, Yang CH. 2014. Novel tumor-targeting, self-assembling peptide nanofiber as a carrier for effective curcumin delivery. Int J Nanomedicine. 9:197–207.
- Liu L, Cao Y, Chen C, Zhang X, McNabola A, Wilkie D, Wilhelm S, Lynch M, Carter C. 2006. Sorafenib blocks the RAF/MEK/ERK pathway, inhibits tumor angiogenesis, and induces tumor cell apoptosis in hepatocellular carcinoma model PLC/PRF/5. Cancer Res. 66:11851–11858.10.1158/0008-5472.CAN-06-1377
- Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF. 2008. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med. 359:378–390.10.1056/NEJMoa0708857
- Maheshwari RK, Singh AK, Gaddipati J, Srimal RC. 2006. Multiple biological activities of curcumin: a short review. Life Sci. 78:2081–2087.10.1016/j.lfs.2005.12.007
- Marshall CJ. 1995. Specificity of receptor tyrosine kinase signaling: transient versus sustained extracellular signal-regulated kinase activation. Cell. 80:179–185.10.1016/0092-8674(95)90401-8
- Martelli AM, Tazzari PL, Tabellini G, Bortul R, Billi AM, Manzoli L, Ruggeri A, Conte R, Cocco L. 2003. A new selective AKT pharmacological inhibitor reduces resistance to chemotherapeutic drugs, TRAIL, all-trans-retinoic acid, and ionizing radiation of human leukemia cells. Leukemia. 17:1794–1805.10.1038/sj.leu.2403044
- Munigunti R, Gathiaka S, Acevedo O, Sahu R, Tekwani B, Calderón AI. 2014. Determination of antiplasmodial activity and binding affinity of curcumin and demethoxycurcumin towards Pf TrxR. Nat Prod Res. 28:359–364.10.1080/14786419.2013.866112
- Sahebkar A. 2015a. Dual effect of curcumin in preventing atherosclerosis: the potential role of pro-oxidant–antioxidant mechanisms. Nat Prod Res. 29:491–492.10.1080/14786419.2014.956212
- Sahebkar A. 2015b. The promise of curcumin–phosphatidylcholine complex for cardiometabolic diseases: more than just ‘more curcumin’. Nat Prod Res. 29:392–393.10.1080/14786419.2014.947494
- Sharma RA, Gescher AJ, Steward WP. 2005. Curcumin: the story so far. Eur J Cancer. 41:1955–1968.10.1016/j.ejca.2005.05.009
- Yao QH, Ye XZ, Wang L, Gu JZ, Fu T, Wang Y, Lai YB, Wang YQ, Wang X, Jin HC, Guo Y. 2013. Protective effect of Curcumin on chemotherapy-induced intestinal dysfunction. Int J Clin Exp Pathol. 6:2342–2349.